Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment.
Peter KamenickỷKarine BriotMaria Luisa BrandiMartine Cohen SolalRachel Katherine CrowleyRichard KeenSami KoltaRobin H LachmannAnne-Lise LecoqStuart H RalstonJennifer S WalshAngela J RylandsAngela WilliamsWei SunAnnabel NixonMark NixonMuhammad Kassim JavaidPublished in: RMD open (2023)
Phase 3: NCT02526160; open-label extension: NCT03920072.